Biosimilars and Biologics in Cancer Treatment
An Era in Therapeutic Strategies
- 1st Edition - April 1, 2026
- Editors: Kuttiappan Anitha, Shvetank Bhatt, Nagaraju Bandaru
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 4 3 8 2 4 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 4 3 8 2 5 - 7
Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses the challenges and opportunities in biosimilars and biologics, integrating the latest eviden… Read more
Purchase options
Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies addresses the challenges and opportunities in biosimilars and biologics, integrating the latest evidence, regulatory landscapes, economic implications, and strategies to enhance cancer management. The book aims to create an all-inclusive educational resource, bridge the gap between research and clinical practice, and inspire future research in oncology. The book provides a comprehensive examination of cancer therapeutics, starting with an introduction to biologics and biosimilars, their historical development, and foundational principles. It explains their mechanisms of action, drug development processes, regulatory landscapes, and clinical applications through case studies. Emerging therapeutic strategies, including combination therapies and personalized medicine, are also covered. This book benefits researchers, oncologists, pharmacologists, pathologists, and other healthcare professionals by offering up-to-date insights into the clinical aspects of biological medications and their biosimilars. Contributions from global experts ensure readers gain the latest advancements and practical guidance on integrating these therapies into clinical practice and research.
- Provides an in-depth analysis of biologics and biosimilars, covering their historical development, mechanisms of action, drug development processes, and regulatory landscapes.
- Includes case studies and practical examples that highlight the use of biologics and biosimilars in cancer treatment, showcasing their efficacy, safety profiles, and emerging therapeutic strategies such as combination therapies and personalized medicine.
- Offers diverse and comprehensive perspectives, ensuring readers gain insights into the latest advancements and future directions in biosimilars and biologics, along with practical guidance for integrating these therapies into clinical practice and research
Researchers and Scientists: Individuals involved in cancer research, particularly those focusing on the development and application of biologics and biosimilars
1. Introduction to Biosimilars and Biologics
2. Opportunities and Challenges in the Biosimilars and Biologics
3. Impact of Biosimilars and Biologics in Cancer Treatment
4. Clinical Applications of Biologics and Biosimilars in Oncology
5. Biosimilars and Biologics in Breast Cancer
6. Biosimilars and Biologics in Gastric and Colorectal Cancer
7. Biosimilars and Biologics in Cervical Cancer
8. Biosimilars and Biologics in Lung Cancer
9. Biosimilars and Biologics in Hepatocellular Carcinoma
10. Biosimilars and Biologics in Brain Tumor
11. Biosimilars and Biologics in Pancreatic Cancer
12. Biosimilars and Biologics in Prostate Cancer
13. Biosimilars and Biologics in Ovarian Cancer
14. Biosimilars and Biologics in Bone Cancer
15. Biosimilars and Biologics in Endometrial/Uterine Cancer
16. Biosimilars and Biologics in Urothelial Carcinoma
17. Biosimilars and Biologics in Melanoma
18. Biologics and Biosimilars from the Bench to the Bedside in Oncology
19. Recent Evidence of Biologics and Biosimilars and its Perspectives on Clinical Advances and Emerging Approaches
20. Marching of Biologics and Biosimilars in Artificial Intelligence and Machine Learning as Tools to Detect Various Cancer
2. Opportunities and Challenges in the Biosimilars and Biologics
3. Impact of Biosimilars and Biologics in Cancer Treatment
4. Clinical Applications of Biologics and Biosimilars in Oncology
5. Biosimilars and Biologics in Breast Cancer
6. Biosimilars and Biologics in Gastric and Colorectal Cancer
7. Biosimilars and Biologics in Cervical Cancer
8. Biosimilars and Biologics in Lung Cancer
9. Biosimilars and Biologics in Hepatocellular Carcinoma
10. Biosimilars and Biologics in Brain Tumor
11. Biosimilars and Biologics in Pancreatic Cancer
12. Biosimilars and Biologics in Prostate Cancer
13. Biosimilars and Biologics in Ovarian Cancer
14. Biosimilars and Biologics in Bone Cancer
15. Biosimilars and Biologics in Endometrial/Uterine Cancer
16. Biosimilars and Biologics in Urothelial Carcinoma
17. Biosimilars and Biologics in Melanoma
18. Biologics and Biosimilars from the Bench to the Bedside in Oncology
19. Recent Evidence of Biologics and Biosimilars and its Perspectives on Clinical Advances and Emerging Approaches
20. Marching of Biologics and Biosimilars in Artificial Intelligence and Machine Learning as Tools to Detect Various Cancer
- Edition: 1
- Published: April 1, 2026
- Language: English
KA
Kuttiappan Anitha
Dr. Kuttiappan Anitha is working as Assistant Professor in School of Pharmacy and Technology Management (SPTM), SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Shirpur. She has broad teaching and research experience. Dr. Anitha is recipient of “Excellence in Academic Award” 2022 from International School of Technology and Sciences Affiliated from Govt. of India. She has guided more than 45 M.Pharm students and more than 10 batches of UG Projects. She has more than 30 publications in both national and international journals. Her area of expertise includes Immunooncology, endocrine areas, Gut Microbiota, infectious Diseases. She has also written several books and many book chapters. She has organized Conferences/seminars at university levels.
Affiliations and expertise
Institute of Management Studies, IndiaSB
Shvetank Bhatt
Dr. Shvetank Bhatt is an accomplished Associate Professor in the School of Health Sciences and Technology at Dr. Vishwanath Karad MIT World Peace University, located in Pune, Maharashtra, India. He holds an M. Pharm degree in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, and a Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. With many years of industrial and academic research experience, Dr. Bhatt specializes in CNS disorders, pain, inflammation, and immuno-oncology. He has received numerous accolades, including the Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award for Best Paper in Pharmacology-IJPER in 2012 and 2014. Dr. Bhatt has published dozens of papers in various national and international journals. Dr. Bhatt is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmacological Society (IPS).
Affiliations and expertise
Dr. Vishwanath Karad MIT World Peace University, IndiaNB
Nagaraju Bandaru
Nagarau Bandaru completed his B. Pharm (2011) and M. Pharm (2013) in Pharmacology from Shri Vishnu College of Pharmacy, Bhimavaram, and earned his PhD (2021) from Acharya Nagarjuna University, Guntur, AP, India. With 10 years of teaching experience, he has published 48 research and review papers, 6 patents, and 8 books. He has presented at numerous national and international seminars and conferences and delivered guest lectures at various Indian universities. His accolades include the Best Teacher award from K L University, Best Researcher, Young Scientist, and Distinguished Alumni awards from Shri Vishnu College of Pharmacy. He has received fellowships such as GPAT AICTE and CSIR NEIST summer research fellowship. His research focuses on Neuropharmacology. He has guided many M. Pharm and B. Pharm student projects and is an approved Ph.D. supervisor at Sandip University and K L University. He has also completed 4 NGO projects and secured funded grants.
Affiliations and expertise
Associate Professor; HOD, Department of Pharmacology, Sandip University School of Pharmaceutical Sciences, India